Table 3.
Estimates of the risk of DRP associated with several drugs administered in NICUs, distributed by cases of DRP and frequency of prescription
| Medicines | Adjusted OR (95% CI)* | Cases of DRP | Frequency of prescriptions | ||
| n | % | n | % | ||
| Amphotericin B | 4.80 (1.49 to 15.40) | 46 | 3.7 | 48 | 1.0 |
| Meropenem | 4.09 (1.74 to 9.60) | 100 | 8.0 | 152 | 3.1 |
| Alprostadil | 3.38 (1.67 to 6.84) | 16 | 1.3 | 33 | 0.7 |
| Vancomycin | 3.34 (1.17 to 9.52) | 97 | 7.7 | 100 | 2.0 |
| Ciprofloxacin | 3.03 (1.34 to 6.85) | 13 | 1.0 | 24 | 0.5 |
| Gentamicin | 2.43 (1.00 to 5.89) | 211 | 16.9 | 518 | 10.5 |
| Cefepime | 1.88 (1.13 to 3.13) | 38 | 3.0 | 193 | 3.9 |
| Amikacin | 1.82 (1.09 to 3.07) | 73 | 5.8 | 181 | 3.7 |
| Omeprazole | 1.66 (1.02 to 2.59) | 28 | 2.2 | 146 | 3.0 |
| Others | 630 | 50.3 | 3522 | 71.6 | |
| Total | 1252 | 100.0 | 4917 | 100.0 | |
*OR adjusted for gestational age, 5 min Apgar <7, neurological disorder, renal disorder and cardiac disorder. The p value for each medicine was <0.05.
DRP, drug-related problem; NICU, neonatal intensive care unit.